IP Library Granted Patent US 7,713,709
Granted Patent B2
US 7,713,709 · App. 11/724,983 · Granted May 11, 2010

Assay for detection of antibodies to lysosomal enzymes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,713,709
App. No.
11/724,983
Granted
May 11, 2010
Kind
B2
Abstract

The present invention relates to methods for screening body fluids or tissues for antibodies, including neutralizing and isotype-specific antibodies, against lysosomal enzymes administered as part of enzyme replacement therapy.

Claims (22)

1. A method for detecting lysosomal enzyme (LE)-specific antibodies in a human comprising the steps of:

(a) contacting a body fluid sample from the human with a first lysosomal enzyme labeled with a capture moiety and a second lysosomal enzyme labeled with a detection moiety to form a LE-specific antibody/lysosomal enzyme complex,

(b) capturing the LE-specific antibody/lysosomal enzyme from step (a) by contacting the LE-specific antibody/lysosomal enzyme complex with a solid support that specifically binds to the capture moiety, and

(c) detecting the presence of captured LE-specific antibody from the body fluid sample by detecting the presence of the second lysosomal enzyme labeled with the detection moiety.

2. The method of claim 1 , wherein the capture moiety of the first lysosomal enzyme is bound to the solid support via non-covalent interaction.

3. The method of claim 2 , wherein the non-covalent interaction is biotin-avidin interaction.

4. The method of claim 1 , wherein the body fluid, first lysosomal enzyme and second lysosomal enzyme are all contacted together in the same solution.

5. The method of claim 1 , wherein the body fluid, first lysosomal enzyme and second lysosomal enzyme are contacted together for at least about 30 minutes prior to step (b).

6. The method of claim 1 , wherein the molar concentration of the first lysosomal enzyme is about the same or less than the molar concentration of the second lysosomal enzyme.

7. The method of claim 1 , wherein the first lysosomal enzyme and the second lysosomal enzyme are used in about equimolar ratios.

8. The method of claim 1 , wherein the limit of detection is less than about 500 ng/mL.

9. The method of claim 1 , wherein the limit of detection is less than about 100 ng/mL.

10. The method of claim 1 , wherein the limit of detection is about 1.7 ng/mL to about 8.5 ng/mL.

11. The method of claim 1 , wherein LE-specific antibodies can be detected from a species selected from the group consisting of human, cynomolgus monkey, feline, canine, rabbit, rat and mouse.

12. The method of claim 11 , wherein the species is human.

13. The method of claim 1 , wherein the body fluid is serum.

14. The method of claim 1 , wherein the first and second lysosomal enzyme are recombinant human arylsulfatase (rhASB).

15. The method of claim 1 , wherein the first and second lysosomal enzyme are recombinant human α-glucosidase (rhGAA).

16. A method for detecting lysosomal enzyme (LE)-specific antibodies in a human comprising the steps of:

(a) capturing the LE-specific antibody in a body fluid sample from the human by contacting the body fluid sample with a first lysosomal enzyme bound to a solid support,

(b) contacting captured LE-specific antibody from step (a) with a second lysosomal enzyme labeled with a detection moiety, and

(c) detecting the presence of captured LE-specific antibody from the serum sample by detecting the presence of the second lysosomal enzyme labeled with the detection moiety.

Assignments (2)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2008
From: ZHAO, BIN; TANIGUCHI, GARY; PRINCE, WILLIAM S.; FOEHR, ERIK; FLAY, LISA A.; WHITE, JOLEEN
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 021588/0046 →